Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222141 · ClinicalTrials.gov registry record · NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7
A NA study, sponsored by Edwards Lifesciences.
- Completed
- Registry status
- NA
- Development phase
- 583
- Enrollment target
NCT03222141 is a NA study that has completed, run by Edwards Lifesciences. The registered enrollment target is 583 participants.
The verdict
NCT03222141, a NA study, has completed, sponsored by Edwards Lifesciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 583 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis, and are in high risk.
Interventions
- DEVICE TAVR Implantation of the THV Prosthesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2013-10 |
| Est. Completion | 2020-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03222141
The ClinicalTrials.gov registry entry for NCT03222141 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAVR Implantation of the THV Prosthesis is the first listed.
NCT03222141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03222141 about?
NCT03222141 is a clinical study titled "PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7". The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis, and are in high risk.
What is the current status of trial NCT03222141?
This trial is currently completed. It is a NA study. The enrollment target is 583 participants. The study started on 2013-10. Estimated completion is 2020-08.
What interventions are being tested in trial NCT03222141?
The interventions under investigation include: TAVR Implantation of the THV Prosthesis (DEVICE).
Who is sponsoring clinical trial NCT03222141?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.